Protein phosphorylation is one of the most common post-translational modifications in cellular signal transduction and participates in cell proliferation, metabolic regulation, immune activation, DNA damage response, neural plasticity, tumor progression, and other processes. Protein phosphatases remove phosphate groups from proteins and, together with protein kinases, determine the intensity, duration, and spatial distribution of phosphorylation signals.

Keywords: protein phosphatase; dephosphorylation; PP2A; PTP; PTEN; Calcineurin; lambda protein phosphatase; phosphorylation validation

Figure 1. Schematic Overview of Protein Phosphorylation and Dephosphorylation Regulation

1 Research Entry Points for Dephosphorylation Regulation

1.1 Why Phosphorylation Signaling Requires a “Shutdown Mechanism”

Phosphorylation is often understood as a marker of signal activation, but cellular signaling is not initiated by kinases alone. Without phosphatase-mediated dephosphorylation, signals would continue to amplify, leading to abnormal cell cycle progression, metabolic imbalance, persistent inflammation, or incorrect cell fate decisions.

(1) Regulating signal intensity

Protein phosphatases can reduce substrate phosphorylation levels, preventing kinase signals from becoming excessively enhanced. For example, the activation levels of MAPK, AKT, STAT, AMPK, and other pathways are all counter-regulated by phosphatases.

(2) Controlling signal duration

Different durations of phosphorylation at the same site may lead to completely different biological outcomes. Transient ERK activation and sustained ERK activation can produce different outputs in cell proliferation, differentiation, or stress responses.

(3) Maintaining spatial specificity of signaling

Protein phosphatases often enable dephosphorylation to occur in specific cellular regions by regulating subcellular localization, scaffold protein binding, or regulatory subunit-mediated substrate selection. The spatial localization of phosphorylation signals is closely related to nuclear transcription, membrane receptor responses, and cytoskeletal remodeling.

1.2 Protein Phosphatase Research Is Not Simply the “Opposite” of Kinase Research

Kinases and phosphatases do not form a simple on/off relationship. Many protein phosphatases themselves are regulated by phosphorylation, methylation, redox status, inhibitory proteins, and regulatory subunits. When studying protein phosphatases, their catalytic subunits, regulatory subunits, substrate specificity, and cellular context should all be considered.

2 Major Classes of Protein Phosphatases

2.1 Serine/Threonine Protein Phosphatases

Serine/threonine protein phosphatases mainly act on phosphorylated serine and phosphorylated threonine sites. Representative members include PP1, PP2A, PP2B/Calcineurin, and PP2C. They are widely involved in cell cycle regulation, metabolism, stress responses, synaptic function, and immune signaling.

2.2 Protein Tyrosine Phosphatases

Protein tyrosine phosphatases (PTPs) mainly act on phosphorylated tyrosine sites and are often associated with receptor tyrosine kinases, immune receptors, cell adhesion, and metabolic signaling. Representative members include PTP1B, SHP1, SHP2, CD45, and multiple receptor-type PTPs.

2.3 Dual-Specificity Phosphatases

Dual-specificity phosphatases (DUSPs) can act on phosphorylated serine/threonine and phosphorylated tyrosine sites. The DUSP/MKP family is commonly involved in MAPK pathway regulation, while the CDC25 family participates in cell cycle control.

2.4 Tool-Type Dephosphorylation Enzymes

Lambda protein phosphatase, alkaline phosphatase, and related enzymes are often used as in vitro dephosphorylation tools to validate protein phosphorylation signals, antibody specificity, band mobility shifts, and phosphoproteomic results. They are more suitable for the experimental validation module rather than as direct evidence of specific intracellular regulatory mechanisms.

3 Serine/Threonine Protein Phosphatases

3.1 PP1 and Regulation of Substrate Specificity

PP1 is an important serine/threonine phosphatase in cells and participates in glycogen metabolism, cell cycle regulation, muscle contraction, RNA processing, and DNA damage response. The PP1 catalytic subunit itself has limited substrate specificity, and its function is highly dependent on regulatory subunits and anchoring proteins.

(1) Metabolic regulation

PP1 can affect glycogen synthesis and breakdown by dephosphorylating proteins related to glycogen metabolism. Its function depends on cell type, regulatory subunits, and insulin/energy status.

(2) Cell cycle

PP1 participates in mitotic exit, chromosome segregation, and nuclear envelope reassembly. If PP1 regulation is disrupted, the cell cycle phosphorylation network may fail to reset properly.

(3) Experimental interpretation

Changes in PP1 expression do not necessarily indicate changes in PP1 function. When studying PP1, substrate phosphorylation, regulatory subunits, enzyme activity, or specific intervention experiments should be combined for interpretation.

3.2 PP2A and Tumor-Suppressive Signaling

PP2A is a multisubunit serine/threonine phosphatase complex composed of catalytic, scaffold, and regulatory subunits. PP2A can regulate AKT, MYC, MAPK, Wnt, and cell cycle-related proteins, and is therefore often regarded as an important tumor-suppressive phosphatase network.

(1) Pathway regulation

PP2A can reduce the phosphorylation levels of multiple pro-proliferation and pro-survival proteins. Reduced PP2A activity may lead to sustained enhancement of AKT, ERK, or MYC-related signaling.

(2) Regulatory subunits determine substrates

The substrate specificity of PP2A is mainly determined by its regulatory subunits. Therefore, detecting only PP2A catalytic subunit expression is insufficient to explain specific pathway changes.

(3) Drug research

Some studies attempt to restore tumor-suppressive function by activating PP2A or inhibiting its endogenous inhibitors. Such experiments should simultaneously detect PP2A activity and downstream substrate phosphorylation status.

3.3 PP2B/Calcineurin and Immune/Neural Signaling

PP2B, also known as Calcineurin, is a Ca²⁺/calmodulin-dependent phosphatase. Its classical function is to dephosphorylate NFAT, allowing NFAT to enter the nucleus and initiate immune-related transcriptional programs.

(1) Immune activation

After T cell receptor stimulation, increased Ca²⁺ signaling can activate Calcineurin and promote NFAT dephosphorylation and nuclear translocation. Calcineurin inhibitors can block this process and are therefore widely used in immunosuppression-related research.

(2) Nervous system

Calcineurin also participates in synaptic plasticity, neurotransmitter release, and neurodegenerative disease-related signaling. Its function is strongly dependent on cell type and stimulus intensity.

(3) Experimental indicators

When studying Calcineurin, total protein expression should not be the only readout. NFAT phosphorylation status, nuclear translocation, and downstream transcriptional output should be examined.

3.4 PP2C and Stress/Metabolic Regulation

Most PP2C family members are Mg²⁺/Mn²⁺-dependent phosphatases and commonly participate in stress responses, AMPK signaling, mitochondrial function, and apoptosis-related regulation. Members of the PPM1 family are important components of PP2C-type phosphatases.

4 Protein Tyrosine Phosphatases

4.1 PTP1B and Metabolic Signaling

PTP1B is a classical non-receptor protein tyrosine phosphatase that negatively regulates insulin receptor- and leptin receptor-related signaling. Enhanced PTP1B activity may reduce insulin signaling efficiency and is therefore commonly studied in insulin resistance, obesity, and metabolic diseases.

When studying PTP1B, phosphorylation changes of IR, IRS, AKT, and other nodes after insulin stimulation should be examined, rather than only PTP1B expression. If AKT phosphorylation is restored after PTP1B inhibition, this more strongly supports its involvement in negative regulation of insulin signaling.

4.2 SHP1 and SHP2 in Immune/Tumor Signaling

SHP1 and SHP2 are both SH2 domain-containing non-receptor protein tyrosine phosphatases, but their functional directions differ. SHP1 is more associated with hematopoietic and immunosuppressive signaling, while SHP2 often positively regulates the RTK-RAS-MAPK pathway and is related to multiple tumor signaling processes.

(1) SHP1

SHP1 often acts as a key molecule in inhibitory receptor signaling in immune cells. Functional deficiency of SHP1 may lead to enhanced immune activation or inflammatory imbalance.

(2) SHP2

SHP2 can connect growth factor receptors with RAS-MAPK signaling. In some tumors, abnormal activation of SHP2 can promote proliferation and therapeutic resistance.

(3) Experimental interpretation

SHP-type phosphatases should not simply be classified as “negative regulators.” In some pathways, SHP2 is instead a positive regulatory node required for signal transmission.

4.3 CD45 and Immune Receptor Signaling

CD45 is an important receptor-type protein tyrosine phosphatase on the surface of leukocytes and participates in the regulation of TCR and BCR signaling thresholds. It can regulate the phosphorylation status of Src family kinases, thereby affecting lymphocyte activation.

CD45 research should combine immune cell subsets, receptor stimulation intensity, Lck/Fyn phosphorylation status, and downstream Ca²⁺/MAPK/NFAT signaling for analysis.

5 Dual-Specificity Phosphatases and MAPK Signal Shutdown

5.1 DUSP/MKP Family

The DUSP/MKP family can remove phosphorylated threonine and phosphorylated tyrosine from MAPKs and directly participates in the shutdown of ERK, JNK, and p38 signaling. Different DUSP members have distinct subcellular localization and MAPK preferences.

(1) ERK signaling regulation

Some DUSP members can negatively regulate the ERK pathway and limit sustained ERK activation after growth factor stimulation. If DUSP expression decreases, ERK signaling may be prolonged and may promote proliferation or migration.

(2) JNK/p38 stress signaling

DUSPs can also regulate JNK- and p38-related stress pathways. In models of inflammation, oxidative stress, and DNA damage, changes in DUSP may affect cell death, inflammatory factor expression, and stress adaptation.

(3) Feedback regulation

DUSPs are often induced as negative feedback genes in the MAPK pathway. Therefore, increased DUSP expression may not be the initial cause of signal shutdown, but rather a feedback response after MAPK activation.

5.2 CDC25 and the Cell Cycle

The CDC25 family belongs to dual-specificity phosphatases and can remove inhibitory phosphorylation sites from CDKs, thereby promoting cell cycle progression. CDC25A, CDC25B, and CDC25C are involved in different stages such as G1/S, S phase, and G2/M, respectively.

In CDC25 research, CDK1/CDK2 phosphorylation status, Cyclin expression, cell cycle distribution, and DNA damage checkpoint indicators should be analyzed together. Detecting CDC25 expression alone is insufficient to determine cell cycle progression capacity.

6 Applications of Lambda Protein Phosphatase in Dephosphorylation Validation

6.1 Positioning of Lambda Protein Phosphatase

Lambda protein phosphatase (λPP) is a commonly used tool enzyme for in vitro dephosphorylation treatment. It can be used to determine whether a protein band, antibody signal, or mass spectrometry peptide depends on phosphorylation modification. It is not used to prove which specific endogenous phosphatase regulates the site inside cells.

6.2 Phospho-Antibody Validation

In Western blotting, λPP treatment can be used to validate phospho-antibody signals. If the phospho-antibody signal decreases markedly after λPP treatment while the total protein signal remains stable, this usually supports that the antibody recognizes a phosphorylation-dependent epitope.

(1) Reasonable result

After λPP treatment, the phospho-protein signal decreases while the total protein signal remains unchanged, indicating that the signal is sensitive to dephosphorylation.

(2) Abnormal result

If the phospho-protein signal does not change, the antibody may be nonspecific, or the lysate may contain inhibitors, metal ion conditions may be inappropriate, the substrate site may be inaccessible, or enzyme activity may be insufficient. A positive substrate control should be included.

(3) Interpretation boundary

λPP treatment cannot directly prove that a specific site has been completely removed. For multi-site proteins, site-specific antibodies, mutants, or mass spectrometry localization should be combined.

6.3 Band Mobility Shift Validation

Many proteins show an upward shift, smear, or multiple bands on SDS-PAGE after phosphorylation. If bands shift downward or merge after λPP treatment, this indicates that the mobility change may be caused by phosphorylation modification.

6.4 Phosphorylation Validation by Mass Spectrometry

In phosphoproteomics, λPP can serve as a dephosphorylation negative control. If phosphopeptide abundance decreases after λPP treatment while non-phosphorylated peptides or total peptides remain stable, this supports that the signal comes from phosphorylation modification. Site confirmation still depends on high-quality MS/MS fragments and localization probability.

7 Dephosphorylation Experimental Design and Result Interpretation

7.1 Sample Preparation

Samples used for λPP or other in vitro phosphatase treatments should avoid phosphatase inhibitors, EDTA, EGTA, and high concentrations of strong detergents. Conventional RIPA lysis buffer is not necessarily suitable for direct λPP reactions.

7.2 Control Setup

Dephosphorylation experiments should not include only treated and untreated groups. At minimum, total protein detection, no-enzyme controls, and reaction efficacy controls should be included. If phospho-antibody specificity is being studied, known phosphorylation-positive samples or stimulated samples should preferably be included.

7.3 Difference Between Kinase Inhibitors and λPP

Kinase inhibitors act on upstream signals inside cells and answer the question, “Is this site regulated by a certain kinase?” λPP acts on in vitro samples and answers the question, “Does this detected signal depend on phosphorylation?” The two cannot replace each other and are best used together.

7.4 Site Mutation and Mass Spectrometry Validation

If the goal is to prove that a certain site is a functional phosphorylation site, Ser/Thr/Tyr site mutation, site-specific antibody validation, or mass spectrometry localization should be further performed. λPP can only prove dephosphorylation sensitivity and cannot independently complete site-level mechanistic validation.

8 Protein Phosphatases in Disease Mechanisms

8.1 Tumors

In tumors, phosphorylation networks often show excessive kinase activation and phosphatase imbalance. Reduced PP2A function, abnormal SHP2 activation, PTEN loss, or abnormal DUSP expression may all affect tumor cell proliferation, survival, migration, and therapeutic resistance.

In tumor research, a single p-AKT or p-ERK readout should not be examined alone. Related phosphatase status, total protein expression, drug treatment response, and cellular functional outputs should also be combined.

8.2 Immune Regulation

The Calcineurin-NFAT axis, SHP1/SHP2, CD45, and the DUSP family all participate in regulating immune cell activation thresholds. In T cells, B cells, macrophages, and NK cells, phosphatase abnormalities may lead to excessive immune activation, immunosuppression, or persistent inflammation.

8.3 Metabolic Diseases

PTP1B, PP1, PP2A, and related phosphatases are closely associated with insulin signaling, glycogen metabolism, and energy homeostasis. In insulin resistance research, focusing only on changes in AKT phosphorylation may overlook upstream receptor dephosphorylation and phosphatase regulation of glycogen metabolism.

8.4 Nervous System Diseases

PP1, PP2A, and Calcineurin participate in synaptic plasticity, Tau protein phosphorylation, neuroinflammation, and neurodegenerative changes. In nervous system phosphorylation research, phosphorylation sites, cell types, and subcellular localization should be emphasized.

9 Common Misinterpretations in Protein Phosphatase Experiments

9.1 Attributing All Decreased Phosphorylation to Kinase Inhibition

Decreased phosphorylation may result from reduced kinase activity, but it may also result from increased phosphatase activity, substrate degradation, decreased total protein, or changes in cellular state. Total protein, kinase activity, and related phosphatase factors should be detected together.

9.2 Examining Only Phosphatase Expression

Phosphatase expression does not equal enzyme activity. Multisubunit phosphatases, phosphatases controlled by inhibitory proteins, and localization-dependent phosphatases may show functional changes even when expression remains unchanged.

9.3 Treating λPP Results as an In Vivo Mechanism

λPP is an in vitro tool enzyme and cannot prove the identity of a specific intracellular phosphatase. In vivo mechanisms require validation through gene knockdown/knockout, inhibitors, interaction experiments, substrate trapping, or enzyme activity detection.

9.4 Ignoring Total Protein and Loading Controls

Changes in phospho-antibody signals must be interpreted together with total protein. If total protein also changes, the phospho-protein signal change may simply reflect differences in protein expression or degradation rather than phosphorylation regulation.

10 Product Selection Related to Protein Phosphatases and Dephosphorylation Validation

10.1 Products Related to Dephosphorylation Validation and Lambda Protein Phosphatase Reaction Systems

10.2 Products for Protein Phosphatases, Regulatory Factors, and Signaling Node Detection

10.3 Protein Phosphatase Inhibitors and Pathway Intervention Tools

10.4 Phosphatase Substrates and Detection Auxiliary Products

The core of protein phosphatase research is not simply to identify “dephosphorylating enzymes,” but to understand how phosphorylation signals are restricted, reset, and validated. Combining mechanistic studies of endogenous phosphatases such as PP2A, Calcineurin, PTPs, PTEN, and CDC25 with in vitro dephosphorylation tools such as lambda protein phosphatase allows more accurate differentiation among pathway activation, signal shutdown, antibody specificity, and site-level mechanisms.

For more related articles, please see below:

[1] Protease & Phosphatase Inhibitor Cocktails: Research Applications and Principles